In vivo kinetics and thrombus accumulation of 67ga-labeled urokinase

Highly purified high and low molecular weight urokinase (H-UK and L-UK) were labeled with ⁶⁷Ga using deferoxamine (DF) as a bifunctional chelating agent. The labeling efficiency was 91.7% for the H-UK, and 90.4% for the L-UK, respectively. The ⁶⁷Ga labeled UK (⁶⁷Ga-DF-UK) fully retained the enzymatic activity of the parent UK. Studies on the in vivo behavior of the ⁶⁷Ga labeled UK in rabbits showed a very rapid blood clearance with half-life of 4 min (⁶⁷Ga-DF-L-UK) to 8 min (⁶⁷Ga-DF-H-UK Studies carried out in rabbits with induced thrombi in the femoral vein showed thrombus-to-blood ⁶⁷Ga-DF-UK activity ratios, 2 h after injection, of 2.00–3.08 for the H-UK, and 0.84–1.65 for the L-UK, respectively, with thrombi aged 4 to 3 days. A dose effect of the ⁶⁷Ga-DF-H-UK on its thrombus accumulation was observed. Gel chromatographic analysis of plasma samples withdrawn from those animals injected with this radiopharmaceutical revealed a reduction of the ⁶⁷Ga-DF-UK effectiveness due to complexation with protein inhibitors. This led to formation of high molecular weight complexes which was reflected in the very fast blood clearance. Its implication in thrombus accumulation is discussed. In conclusion, usefulness of DF for labeling UK with ⁶⁷Ga or ⁶⁸Ga with no alteration of UK enzymatic properties was demonstrated. The use of ⁶⁷Ga-DF-UK as a diagnostic or therapeutic radiopharmaceutical is promising.